Joanne Nazif

1 week ago | contemporarypediatrics.com | Tina Tan |Albert Rizzo |Joanne Nazif

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent advancements in RSV prevention, including maternal vaccination and long-acting monoclonal antibodies, are beginning to shift the clinical conversation from reactive management to proactive protection.

1 week ago | contemporarypediatrics.com | Tina Tan |Albert Rizzo |Joanne Nazif

As the field of RSV prevention continues to grow, pediatricians face both new opportunities and new challenges. From emerging immunoprophylaxis strategies to gaps in clinician and parent education, effective RSV management requires staying ahead of a changing landscape.

1 week ago | hcplive.com | Albert Rizzo |Tina Tan |Joanne Nazif

CommentaryVideoJune 16, 2025Author(s):,Fact checked by:,In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education. In this special report from HCP Live and Contemporary Pediatrics RX Review, Albert Rizzo, MD, moderates a discussion with Tina Tan, MD, and Joanne Nazif, MD, to address critical unmet needs and recent FDA approvals that are shaping pediatric respiratory syncytial virus (RSV) management.